Atherosclerosis
Volume 170, Issue 1 , Pages 1-9 , September 2003

Lipoprotein lipase and atherosclerosis

  • Y. Stein

      Affiliations

    • Lipid Research Laboratory, Division of Medicine, Hadassah University Hospital, P.O.B. 12 220, Jerusalem 91120, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-2-677-6928; fax: +972-2-643-4701
    • ,
  • O. Stein

      Affiliations

    • Department of Experimental Medicine and Cancer Research, Hebrew University-Hadassah Medical School, Jerusalem, Israel

Received 9 September 2002 ,Revised 2 January 2003 ,Accepted 9 January 2003.

References 

  1. Deeb SS, Peng RL. Structure of the human lipoprotein lipase gene. Biochemistry. 1989;28(10):4131–4135
  2. Chajek T, Stein O, Stein Y. Lipoprotein lipase of cultured mesenchymal rat heart cells. I. Synthesis, secretion and releasability by heparin. Biochim. Biophys. Acta. 1978;528:456–465
  3. Stein O, Stein Y, Pressman-Schwartz S, Reshef A, Chajek-Shaul T, Ben-Naim M, et al. Expression of lipoprotein lipase mRNA in rat heart is localized mainly to mesenchymal cells as studied by in-situ hybridization. Arterioscler. Thromb. 1991;11:857–863
  4. Chajek-Shaul T, Friedman G, Halperin G, Stein O, Stein Y. Uptake of chylomicron [3H]cholesteryl linoleyl ether by mesenchymal rat heart cell cultures. Biochim. Biophys. Acta. 1981;666(1):147–155
  5. Friedman G, Chajek-Shaul T, Stein O, Olivecrona T, Stein Y. The role of lipoprotein lipase in the assimilation of cholesteryl linoleyl ether by cultured cells incubated with labeled chylomicrons. Biochim. Biophys. Acta. 1981;666(1):156–164
  6. Chajek-Shaul T, Friedman G, Halperin G, Stein O, Stein Y. Role of lipoprotein lipase in the uptake of cholesteryl ester by rat lactating mammary gland in vivo. Biochim. Biophys. Acta. 1981;666(2):216–222
  7. Stein O, Ben-Naim M, Dabach Y, Hollander G, Halperin G, Stein Y. Can lipoprotein lipase be the culprit in cholesteryl ester accretion in smooth muscle cells in atheroma. Atherosclerosis. 1993;99(1):15–22
  8. Jonasson L, Bondjers G, Hansson GK. Lipoprotein lipase in atherosclerosis: its presence in smooth muscle cells and absence from macrophages. J. Lipid Res. 1987;28(4):437–445
  9. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg IJ, Steinberg D, Witztum JL. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 1991;88(22):10143–10147
  10. O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J. Clin. Invest. 1992;89(5):1544–1550
  11. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis. FEBS Lett. 1999;462(1–2):1–6
  12. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr. Opin. Lipidol. 1995;6(5):291–305
  13. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 1996;37(4):693–707
  14. Beisiegel U. New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis. Atherosclerosis. 1996;124(1):1–8
  15. Markku O, Pentikainen MO, Oksjoki R, Oorni K, Kovanen PT. Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler. Thromb. Vasc. Biol. 2002;22(2):211–217
  16. Zilversmit DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ. Res. 1973;33(6):633–638
  17. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 1999;103(12):1697–1705
  18. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J. Biol. Chem. 2000;275(34):26293–26299
  19. Van Eck M, Zimmermann R, Groot PH, Zechner R, Van Berkel TJ. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000;20(9):E53–E62
  20. Wilson K, Fry GL, Chappell DA, Sigmund CD, Medh JD. Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice. Arterioscler. Thromb. Vasc. Biol. 2001;21(11):1809–1815
  21. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J. Lipid Res. 2000;41(4):521–531
  22. Beauchamp MC, Letendre E, Renier G. Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia. J. Lipid Res. 2002;43(2):215–222
  23. Beauchamp MC, Renier G. Homocysteine induces protein kinase C activation and stimulates c-Fos and lipoprotein lipase expression in macrophages. Diabetes. 2002;51(4):1180–1187
  24. Corey JE, Zilversmit DB. Effect of cholesterol feeding on arterial lipolytic activity in the rabbit. Atherosclerosis. 1977;27(2):201–212
  25. Werba JP, Martinet V, Abulafia DP, Levy R, Magarinos G, Rey RH, et al. Marked neointimal lipoprotein lipase increase in distinct models of proclivity to atherosclerosis: a feature independent of endothelial layer integrity. Atherosclerosis. 2001;156(1):91–101
  26. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA. 1991;88(19):8342–8346
  27. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J. Clin. Invest. 1992;90(5):2013–2021
  28. Tabas I, Li Y, Brocia RW, Xu SW, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J. Biol. Chem. 1993;268(27):20419–20432
  29. Stein O, Halperin G, Stein Y. Biological labeling of very low density lipoproteins with cholesteryl linoleyl ether and its fate in the intact rat. Biochim. Biophys. Acta. 1980;620:247–260
  30. Stein Y, Dabach Y, Hollander G, Halperin G, Stein O. M Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether. Biochim. Biophys. Acta. 1983;752(1):98–105
  31. Chajek-Shaul T, Friedman G, Stein O, Olivecrona T, Stein Y. Binding of lipoprotein lipase to the cell surface is essential for the transmembrane transport of chylomicron cholesteryl ester. Biochim. Biophys. Acta. 1982;712(1):200–210
  32. Stein O, Friedman G, Chajek-Shaul T, Halperin G, Olivecrona T, Stein Y. Transfer of cholesteryl linoleyl ether from phosphatidylcholine and phosphatidylethanolamine liposomes to cultured cells catalyzed by lipoprotein lipase. Biochim. Biophys. Acta. 1983;750(2):306–316
  33. Seo T, Al-Haideri M, Treskova E, Worgall TS, Kako Y, Goldberg IJ, et al. Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1. J. Biol. Chem. 2000;275(39):30355–30362
  34. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271(5248):518–520
  35. Leitersdorf E, Stein O, Eisenberg S, Stein Y. Uptake of rat plasma HDL subfractions labeled with [3H]cholesteryl linoleyl ether or with 125I by cultured rat hepatocytes and adrenal cells. Biochim. Biophys. Acta. 1984;796(1):72–82
  36. Glass C, Pittman RC, Civen M, Steinberg D. Uptake of high-density lipoprotein-associated apoprotein A-l and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J. Biol. Chem. 1985;260:744–750
  37. Israeli A, Leitersdorf E, Stein O, Stein Y. Preferential binding of [3H]cholesteryl linoleyl ether-HDL3 by bovine adrenal membranes. Biochim. Biophys. Acta. 1987;902:128–132
  38. Rinninger F, Kaiser T, Mann WA, Meyer N, Greten H, Beisiegel U. Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture. J. Lipid Res. 1998;39(7):1335–1348
  39. Rinninger F, Brundert M, Brosch I, Donarski N, Budzinski RM, Greten H. Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI. J. Lipid Res. 2001;42(11):1740–1751
  40. Merkel M, Kako Y, Radner H, Cho IS, Ramasamy R, Brunzell JD, et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc. Natl. Acad. Sci. USA. 1998;95(23):13841–13846
  41. Merkel M, Heeren J, Dudeck W, Rinninger F, Radner H, Breslow JL, et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J. Biol. Chem. 2002;277(9):7405–7411
  42. Shimada M, Ishibashi S, Inaba T, Yagyu H, Harada K, Osuga JI, et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 1996;93(14):7242–7246
  43. Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, et al. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J. Lipid Res. 1999;40(9):1677–1685
  44. Fan J, Unoki H, Kojima N, Sun H, Shimoyamada H, Deng H, et al. Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 2001;276(43):40071–40079
  45. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 1993;92(1):411–417
  46. Chiba T, Miura S, Sawamura F, Uetsuka R, Tomita I, Inoue Y, et al. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler. Thromb. Vasc. Biol. 1997;17(11):2601–2608
  47. Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am. J. Cardiol. 2001;88(12A):24N–29
  48. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15(19):5336–5348
  49. Carroll R, Severson DL. Peroxisome proliferator-activated receptor-alpha ligands inhibit cardiac lipoprotein lipase activity. Am. J. Physiol. Heart Circ. Physiol. 2001;281(2):H888–H894
  50. Michaud SE, Renier G. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes. 2001;50(3):660–666
  51. Sartippour MR, Renier G. Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose: role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. Arterioscler. Thromb. Vasc. Biol. 2000;20(1):104–110
  52. Sartippour MR, Renier G. Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Diabetes. 2000;49(4):597–602
  53. Gbaguidi FG, Chinetti G, Milosavljevic D, Teissier E, Chapman J, Olivecrona G, et al. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett. 2002;512(1–3):85–90
  54. Li L, Beauchamp MC, Renier G. Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis. 2002;165(1):101–110
  55. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, et al. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol. Pharmacol. 2001;59(2):170–176
  56. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ. Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ. J. Biol. Chem. 2001;276(46):43018–43024
  57. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 2002;22(8):2607–2619
  58. Schneider J, Kreuzer J, Hamann A, Nawroth PP, Dugi KA. The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes. 2002;51(3):867–870
  59. Gagne SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, Wilson PW, et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin. Genet. 1999;55(6):450–454
  60. Reymer PW, Gagne E, Groenemeyer BE, Zhang H, Forsyth I, Jansen H, et al  A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 1995;10(1):28–34
  61. Regression Growth Evaluation Statin Study, Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagne E, Hayden MR, Kastelein JJ. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Circulation 1996;94(8)1913–18.
  62. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol. Ther. 1996;70(2):101–135
  63. Kuivenhoven JA, Groenemeyer BE, Boer JM, Reymer PW, Berghuis R, Bruin T, et al. Ser447 stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler. Thromb. Vasc. Biol. 1997;17(3):595–599
  64. Groenemeijer BE, Hallman MD, Reymer PW, Gagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. Circulation 1997;95(12):2628–35.
  65. Chen L, Patsch W, Boerwinkle E. HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis. Hum. Genet. 1996;98(5):551–556
  66. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin. Genet. 2001;60(4):293–300
  67. The European Atherosclerosis Research Study (EARS) Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides. Arterioscler. Thromb. Vasc. Biol. 1998;18(4):526–534
  68. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis. 2001;159(2):367–373
  69. Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagne SE, et al. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin. Genet. 1999;56(4):297–305
  70. Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, et al. Interaction of the lipoprotein lipase asparagine 291—>serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. J. Lipid Res. 1995;36:2104–2112
  71. Talmud PJ, Bujac SR, Hall S, Miller GJ, Humphries SE. Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers. Atherosclerosis. 2000;149(1):75–81
  72. Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis. 1995;118(Suppl.):S11–S27
  73. Friedlander Y, Leitersdorf E, Vecsler R, Funke H, Kark J. The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge. Atherosclerosis. 2000;152(1):239–248
  74. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis. 2001;157(1):123–129
  75. McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL); effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis. 2001;156(2):401–407
  76. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene; effects on plasma lipids and risk of atherosclerosis. Atherosclerosis. 1997;135(2):145–159
  77. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int. J. Clin. Lab. Res. 1997;27(1):24–34
  78. Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, et al. Ethnic variation and in vivo effects of the -93t—>g promoter variant in the lipoprotein lipase gene. Arterioscler. Thromb. Vasc. Biol. 1997;17(11):2672–2678
  79. Larson I, Hoffmann MM, Ordovas JM, Schaefer EJ, Marz W, Kreuzer J. The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. Clin. Chem. 1999;45(7):963–968
  80. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99(22):2901–2907
  81. Talmud PJ, Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr. Opin. Lipidol. 2001;12(4):405–409
  82. Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, et al. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim. Biophys. Acta. 1996;1302(2):159–166
  83. Mead JR, Ramji DP. The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc. Res. 2002;55:261–269
  84. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake and regulation, J Lipid Res 2002;43:1997–2006.
  85. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease, J Mol Med 2002;80:753–69.

PII: S0021-9150(03)00014-5

doi: 10.1016/S0021-9150(03)00014-5

Atherosclerosis
Volume 170, Issue 1 , Pages 1-9 , September 2003

Article Tools